Selegiline for Smoking Cessation - 1

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is designed to examine the effects of Selegiline Transdermal System and behavioral intervention in smoking cessation as compared to behavioral intervention alone.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Institute on Drug Abuse (NIDA)
• Collaborator: VA Office of Research and Development
• Treatments: Selegiline

Criteria

Inclusion Criteria:

• Must be at least 18 years of age

• Be in good general health

• Must meet Diagnostic and Statistical Manual-IV (DSM-IV) diagnostic criteria for nicotine dependence

• Be currently smoking > 15 cigarettes/day, and have smoked cigarettes for the past 5 years

• Subjects must be motivated to quite smoking

• If female and of child bearing potential, agrees to use birth control and subject

• Subject must be able to understand and provide written informed consent.

Exclusion

Criteria:

• Please contact site for more information